Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Identifying hospital-acquired infections using retrospective record review from the Irish National Adverse Events Study (INAES) and European point prevalence survey case definitions.

Rafter N, Finn R, Burns K, Condell S, Conroy RM, Hickey A, O'Connor P, Vaughan D, Walsh G, Williams DJ.

J Hosp Infect. 2019 Mar;101(3):313-319. doi: 10.1016/j.jhin.2018.12.011. Epub 2018 Dec 24.

PMID:
30590090
2.

Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials.

Selak V, Webster R, Stepien S, Bullen C, Patel A, Thom S, Arroll B, Bots ML, Brown A, Crengle S, Dorairaj P, Elley CR, Grobbee DE, Harwood M, Hillis GS, Laba TL, Neal B, Peiris D, Rafter N, Reid C, Stanton A, Tonkin A, Usherwood T, Wadham A, Rodgers A.

Heart. 2019 Jan;105(1):42-48. doi: 10.1136/heartjnl-2018-313108. Epub 2018 Jun 28.

3.

Healthcare expenditure on Indigenous and non-Indigenous Australians at high risk of cardiovascular disease.

Angell B, Laba TL, Lung T, Brown A, Eades S, Usherwood T, Peiris D, Billot L, Hillis G, Webster R, Tonkin A, Reid C, Molanus B, Rafter N, Cass A, Patel A, Jan S.

Int J Equity Health. 2017 Jun 23;16(1):108. doi: 10.1186/s12939-017-0610-2.

4.

The impact of a point-of-care testing device on CVD risk assessment completion in New Zealand primary-care practice: A cluster randomised controlled trial and qualitative investigation.

Wells S, Rafter N, Kenealy T, Herd G, Eggleton K, Lightfoot R, Arcus K, Wadham A, Jiang Y, Bullen C.

PLoS One. 2017 Apr 19;12(4):e0174504. doi: 10.1371/journal.pone.0174504. eCollection 2017.

5.

Using run charts for cardiovascular disease risk assessments in general practice.

Wells S, Rafter N, Eggleton K, Turner C, Huang Y, Bullen C.

J Prim Health Care. 2016 Jun;8(2):172-8. doi: 10.1071/HC15030.

PMID:
27477560
6.

Dispensing data captures individual-level use of aspirin for cardiovascular disease prevention, despite availability over-the-counter.

Selak V, Gu Y, Rafter N, Crengle S, Kerr AJ, Bullen C.

N Z Med J. 2016 May 27;129(1435):21-8.

PMID:
27355165
7.

Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease.

Selak V, Bullen C, Stepien S, Arroll B, Bots M, Bramley D, Cass A, Grobbee D, Hillis GS, Molanus B, Neal B, Patel A, Rafter N, Rodgers A, Thom S, Tonkin A, Usherwood T, Wadham A, Webster R.

Eur J Prev Cardiol. 2016 Sep;23(13):1393-400. doi: 10.1177/2047487316638216. Epub 2016 Mar 4. Review.

PMID:
26945024
8.

Polypill-based therapy likely to reduce ethnic inequities in use of cardiovascular preventive medications: Findings from a pragmatic randomised controlled trial.

Selak V, Harwood M, Raina Elley C, Bullen C, Wadham A, Parag V, Rafter N, Arroll B, Bramley D, Crengle S.

Eur J Prev Cardiol. 2016 Sep;23(14):1537-45. doi: 10.1177/2047487316637196. Epub 2016 Feb 29.

PMID:
26928727
9.

The Irish National Adverse Events Study (INAES): the frequency and nature of adverse events in Irish hospitals-a retrospective record review study.

Rafter N, Hickey A, Conroy RM, Condell S, O'Connor P, Vaughan D, Walsh G, Williams DJ.

BMJ Qual Saf. 2017 Feb;26(2):111-119. doi: 10.1136/bmjqs-2015-004828. Epub 2016 Feb 9.

10.

Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries.

Webster R, Patel A, Selak V, Billot L, Bots ML, Brown A, Bullen C, Cass A, Crengle S, Raina Elley C, Grobbee DE, Neal B, Peiris D, Poulter N, Prabhakaran D, Rafter N, Stanton A, Stepien S, Thom S, Usherwood T, Wadham A, Rodgers A; SPACE Collaboration.

Int J Cardiol. 2016 Feb 15;205:147-156. doi: 10.1016/j.ijcard.2015.12.015. Epub 2015 Dec 14.

11.

The Effect of a Cardiovascular Polypill Strategy on Pill Burden.

Truelove M, Patel A, Bompoint S, Brown A, Cass A, Hillis GS, Peiris D, Rafter N, Reid CM, Rodgers A, Tonkin A, Usherwood T, Webster R; Kanyini GAP Collaboration.

Cardiovasc Ther. 2015 Dec;33(6):347-52. doi: 10.1111/1755-5922.12151.

PMID:
26280247
12.

An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial.

Laba TL, Hayes A, Lo S, Peiris DP, Usherwood T, Hillis GS, Rafter N, Reid CM, Tonkin AM, Webster R, Neal BC, Cass A, Patel A, Rodgers A, Jan S.

Med J Aust. 2014 Dec 11;201(11):671-3.

PMID:
25495315
13.

Adverse events in healthcare: learning from mistakes.

Rafter N, Hickey A, Condell S, Conroy R, O'Connor P, Vaughan D, Williams D.

QJM. 2015 Apr;108(4):273-7. doi: 10.1093/qjmed/hcu145. Epub 2014 Jul 29. Review.

PMID:
25078411
14.

Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.

Selak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N, Parag V, Harwood M, Doughty RN, Arroll B, Milne RJ, Bramley D, Bryant L, Jackson R, Rodgers A.

BMJ. 2014 May 27;348:g3318. doi: 10.1136/bmj.g3318.

15.

A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.

Patel A, Cass A, Peiris D, Usherwood T, Brown A, Jan S, Neal B, Hillis GS, Rafter N, Tonkin A, Webster R, Billot L, Bompoint S, Burch C, Burke H, Hayman N, Molanus B, Reid CM, Shiel L, Togni S, Rodgers A; Kanyini Guidelines Adherence with the Polypill (Kanyini GAP) Collaboration.

Eur J Prev Cardiol. 2015 Jul;22(7):920-30. doi: 10.1177/2047487314530382. Epub 2014 Mar 27.

PMID:
24676715
16.

The body image scale: a simple and valid tool for assessing body image dissatisfaction in inflammatory bowel disease.

McDermott E, Moloney J, Rafter N, Keegan D, Byrne K, Doherty GA, Cullen G, Malone K, Mulcahy HE.

Inflamm Bowel Dis. 2014 Feb;20(2):286-90. doi: 10.1097/01.MIB.0000438246.68476.c4.

PMID:
24374873
17.

Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: the SPACE Collaboration.

Webster R, Patel A, Billot L, Cass A, Burch C, Neal B, Usherwood T, Thom S, Poulter N, Stanton A, Bots ML, Grobbee DE, Prabhakaran D, Reddy KS, Field J, Bullen C, Elley CR, Selak V, Rafter N, Wadham A, Berwanger O, Rodgers A; SPACE Collaboration.

Int J Cardiol. 2013 Dec 5;170(1):30-5. doi: 10.1016/j.ijcard.2013.10.007. Epub 2013 Oct 12.

PMID:
24144927
18.

Recruiting equal numbers of indigenous and non-indigenous participants to a 'polypill' randomized trial.

Selak V, Crengle S, Elley CR, Wadham A, Harwood M, Rafter N, Bullen C, Pillai A, Arroll B, Rodgers A.

Int J Equity Health. 2013 Jun 22;12:44. doi: 10.1186/1475-9276-12-44.

19.

More than a feeling: integrating empathy into the study of lawmaking, lawbreaking, and reactions to lawbreaking.

Posick C, Rocque M, Rafter N.

Int J Offender Ther Comp Criminol. 2014 Jan;58(1):5-26. doi: 10.1177/0306624X12465411. Epub 2012 Nov 26.

PMID:
23188925
20.

IMProving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care.

Selak V, Elley CR, Crengle S, Harwood M, Doughty R, Arroll B, Bryant L, Rafter N, Hoorn SV, Wadham A, Wells S, Milne R, Jackson R, Bramley D, Rodgers A.

Contemp Clin Trials. 2011 Nov;32(6):909-15. doi: 10.1016/j.cct.2011.07.006. Epub 2011 Jul 18.

PMID:
21777702
21.

An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk.

PILL Collaborative Group, Rodgers A, Patel A, Berwanger O, Bots M, Grimm R, Grobbee DE, Jackson R, Neal B, Neaton J, Poulter N, Rafter N, Raju PK, Reddy S, Thom S, Vander Hoorn S, Webster R.

PLoS One. 2011;6(5):e19857. doi: 10.1371/journal.pone.0019857. Epub 2011 May 25.

22.

Cardiovascular treatment gaps: closing, but slowly.

Selak V, Rafter N, Parag V, Tomlin A, Vander Hoorn S, Dovey S, Rodgers A.

N Z Med J. 2009 Apr 24;122(1293):3564.

PMID:
19448790
23.

Integrated electronic decision support increases cardiovascular disease risk assessment four fold in routine primary care practice.

Wells S, Furness S, Rafter N, Horn E, Whittaker R, Stewart A, Moodabe K, Roseman P, Selak V, Bramley D, Jackson R.

Eur J Cardiovasc Prev Rehabil. 2008 Apr;15(2):173-8. doi: 10.1097/HJR.0b013e3282f13af4.

PMID:
18391644
24.

Gaps in primary care documentation of cardiovascular risk factors.

Rafter N, Wells S, Stewart A, Selak V, Whittaker R, Bramley D, Roseman P, Furness S, Jackson RT.

N Z Med J. 2008 Feb 15;121(1269):24-33.

PMID:
18278079
25.

Will a web-based cardiovascular disease (CVD) risk assessment programme increase the assessment of CVD risk factors for Maori?

Whittaker R, Bramley D, Wells S, Stewart A, Selak V, Furness S, Rafter N, Roseman P, Jackson R.

N Z Med J. 2006 Jul 21;119(1238):U2077.

PMID:
16868574
26.

Cardiovascular medications in primary care: treatment gaps and targeting by absolute risk.

Rafter N, Connor J, Hall J, Jackson R, Martin I, Parag V, Vander Hoorn S, Rodgers A.

N Z Med J. 2005 Oct 7;118(1223):U1676.

PMID:
16224500
27.

Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review.

Connor J, Rafter N, Rodgers A.

Bull World Health Organ. 2004 Dec;82(12):935-9. Epub 2005 Jan 5. Review.

Supplemental Content

Loading ...
Support Center